• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters

    2/27/25 9:02:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email
    • TOTAL30 for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens,1-3 is now available in expanded parameters
    • Features the same 95% fit success rate and innovative PRECISION BALANCE 8|4 technology4*
    • New expanded parameters help more astigmatic patients address unmet needs for comfort5 and convenience in a monthly lens

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens,1-3 delivering the same exceptionally comfortable wearing experience,5 now in a –2.75D cylinder offering.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227161413/en/

    TOTAL30 for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens, is now available in expanded parameters. (Photo: Business Wire)

    TOTAL30 for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens, is now available in expanded parameters. (Photo: Business Wire)

    Astigmatic patients, making up 47% of the patient population,6 are even more likely to suffer from dryness and discomfort.7 As the leading cause of dropout,8 contact lens discomfort not only impacts patients' ability to enjoy freedom from glasses but can also affect their day-to-day lives. TOTAL30 for Astigmatism with expanded parameters is bridging the divide, providing patients with proven stability, and TOTAL comfort all month long,5 at an affordable price.

    "Alcon's continued investment in reusable innovation aims to better serve the 61%9 of Canadian contact lens wearers choosing reusable lenses," said Jeroen Bastemeijer, General Manager of Alcon Canada. "By introducing expanded -2.75D cylinder parameters in TOTAL30 for Astigmatism, Alcon facilitates Eye Care Professionals (ECPs) in addressing the diverse needs of today's patients, allowing them to experience TOTAL comfort all month long."5

    As with the entire WaterInnovations™ Toric family, TOTAL30 for Astigmatism lenses in expanded parameters are equipped with Alcon's proprietary PRECISION BALANCE 8|4® lens design,4,10,11 providing the on-eye stability astigmatic contact lens wearers need for exceptionally clear and stable vision,12 as well as a 95% first lens fit success rate.4* They also feature Class 1 UV blocking against UVA and UVB rays,13-15† and Blue-Violet Light (BVL) filtration‡ for reduced exposure.13

    Alcon's dedication to expanding access to eye care includes ensuring all patients are equipped with the necessary information they need to make eye health decisions. That is why ECPs will be able to utilize informative materials about TOTAL30 for Astigmatism in expanded parameters in English and French. For access to the materials, ECPs can reach out to their Alcon representatives, and for more ECP to patient digital resources, visit AlconVisionBrandLibrary.com

    "It is truly exciting that the reusable lens I have come to trust most for my astigmatic patients is now available in expanded cylinder parameters," said Dr. Pavan Avinashi, Doctor of Optometry at the Hollyburn Eye Clinic in Vancouver. "Total30 has redefined the reusable contact lens market, providing all the innovations of Water Gradient Technology,2,3 UV Blocking,13-15† Blue-Violet Light Filtration,13‡ quick time to settle,4 and incredible first lens fit success.4* With the new -2.75D cylinder options, I can now fit close to 100% of my astigmatic patients,** allowing even more people to experience this impressive technology."

    TOTAL30 for Astigmatism in expanded parameters is now available across Canada. For more information, please visit www.alcon.ca

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca

    References

    1. Shi X, Cantu-Crouch D, Sharma V, et al. Surface characterization of a silicone hydrogel contact lens having bioinspired 2-methacryloyloxyethyl phosphorylcholine polymer layer in hydrated state. Colloids Surf B: Biointerfaces. March 2021;199:111539.
    2. Surface property analysis of lehfilcon A lenses out of pack and after 30 days of wear; Alcon data on file, 2021.
    3. Surface observations of lehfilcon A contact lens and human cornea using scanning transmissions electron microscopy; Alcon data on file, 2021.
    4. In a study where n=69; Alcon data on file, 2021.
    5. Alcon data on file, 2021.
    6. Young G, Sulley A, Hunt C. Prevalence of astigmatism in relation to soft contact lens fitting. Eye Contact Lens. 2011;37:20-25.
    7. Multi Sponsor Surveys Inc. The 2014 Gallup target market report on the market for toric contact lenses.
    8. Alcon data on file, 2021.
    9. Canadian CLI Market Share as of Q2 2023 (Reusable lenses include Monthly and Bi-Weekly replacement schedules).
    10. Alcon data on file, 2020.
    11. In a study where n=47, Alcon data on file, 2020.
    12. Alcon data on file, 2021.
    13. Laboratory assessment of ultraviolet and visible light transmission properties of lehfilcon A sphere contact lenses using spectrophotometer; Alcon data on file, 2020.
    14. ISO 18369-2:2017 Ophthalmic optics — Contact lenses Part 2: Tolerances.
    15. ANSI Z80.20-2016 ophthalmic contact lens UV transmittance.

    *Based on lens movement, centration and orientation at initial fitting.

    **Covers 99% of astigmats. Coverage of astigmatic patients with a -3.00D cylinder or lower.

    †UV absorbing contact lenses are NOT substitutes for protective UV absorbing eyewear, such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. The patient should continue to use UV absorbing eyewear as directed.

    ‡There is no demonstrated clinical benefit to reduction in blue-violet light at wavelengths below 450 nm. BVL testing done on lehfilcon A sphere lenses.

    See product instructions for complete wear, care, and safety information. Rx only.

    Connect with us on

    Facebook

    LinkedIn

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250227161413/en/

    Media Relations

    Jane Lee Cheung

    +1 289 290 2393 (Toronto)

    [email protected]

    Get the next $ALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC

    DatePrice TargetRatingAnalyst
    1/30/2026Mkt Perform
    William Blair
    1/20/2026Hold → Buy
    Deutsche Bank
    1/9/2026Buy → Hold
    Stifel
    12/11/2025$75.00Buy → Underperform
    BofA Securities
    8/21/2025Overweight → Neutral
    Analyst
    5/20/2025Buy → Hold
    Deutsche Bank
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    3/28/2025$107.00 → $110.00Buy
    Needham
    More analyst ratings

    $ALC
    SEC Filings

    View All

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    1/6/26 8:19:06 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form DFAN14A filed by Alcon Inc.

    DFAN14A - ALCON INC (0001167379) (Filed by)

    12/9/25 8:56:17 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    11/12/25 6:18:28 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens to Start and End Every Week Fresh

    PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision even on day 71 Features world's first ACTIV-FLO System specially designed for one-week optimal performance2 Now available in Canada, PRECISION7 broadens existing WaterInnovations portfolio, addressing the need for 16 hours of outstanding comfort and affordability when a daily disposable lens is not an option1,3 Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the Canadian launch of PRECISION7® sphere and toric, the only one-week replacement contact lens with the revolutionary ACTIV-FLO® System2,5 that provides 16 h

    2/2/26 9:02:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Completes $750 Million Share Repurchase Program

    Alcon Inc., the global leader in eye care dedicated to helping people see brilliantly, today announced the completion of its $750 million share repurchase program, which commenced on April 1, 2025. In aggregate, 9,301,877 registered shares were acquired on the SIX Swiss Exchange, representing 1.9% of the current share capital of Alcon Inc. The total buyback volume amounted to CHF 602 million (USD 750 million). The registered shares acquired will be held in treasury and are intended to offset the dilutive effect of registered shares vesting under Alcon's equity-based incentive plans. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage span

    1/20/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Terminates Agreement to Acquire STAAR Surgical

    Ad hoc announcement pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ:STAA) announced on August 5, 2025. "Throughout this process we remained disciplined with our views on price and risk. Moving forward, our refractive strategy is unchanged and our new wavelight® plus offering remains our focus for the most popular refractive surgery in the world, LASIK. This will be an exciting year for Alcon as we continue the global launches of more than 10 major products in both our surgical and vision care franchises. These innovations substantiv

    1/6/26 8:00:00 PM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Alcon

    William Blair initiated coverage of Alcon with a rating of Mkt Perform

    1/30/26 6:43:20 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon upgraded by Deutsche Bank

    Deutsche Bank upgraded Alcon from Hold to Buy

    1/20/26 8:36:02 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon downgraded by Stifel

    Stifel downgraded Alcon from Buy to Hold

    1/9/26 8:47:33 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/23 1:35:38 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/22 5:01:03 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Leadership Updates

    Live Leadership Updates

    View All

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $ALC
    Financials

    Live finance-specific insights

    View All

    Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds

    Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c

    11/11/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

    Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month

    8/19/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care